Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,278 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer Clear all
Terminated Phase 1 Interventional

Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer

NCT00524186
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
fluorouracil, irinotecan hydrochloride, leucovorin calcium, sunitinib malate, flow cytometry, pharmacological study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

NCT01286454
View directory record Official record
Conditions
Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
Interventions
fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating LXR-623 in Healthy Subjects

NCT00366522
View directory record Official record
Conditions
Healthy
Interventions
LXR-623
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
19 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 2 Interventional Results available

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

NCT01006122
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy
Interventions
Placebo, PF-03654746
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 30, 2026, 6:13 AM EDT
Terminated Phase 3 Interventional Results available

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

NCT00811018
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sitaxsentan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 30, 2026, 6:13 AM EDT
Completed No phase listed Observational Results available

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

NCT06504524
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Standard of Care
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML

NCT00574873
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Bosutinib, imatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
32
States / cities
Anaheim, California • Beverly Hills, California • Fountain Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 2 Interventional Results available

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

NCT00201773
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Celecoxib, Correlative studies
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 4 Interventional

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

NCT00147654
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
95
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 3 Interventional

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

NCT00001017
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 4 Interventional Results available

An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents

NCT03405818
View directory record Official record
Conditions
Onychomycosis, Tinea Unguium
Interventions
Tavaborole 5% Topical Solution
Drug
Lead sponsor
Pfizer
Industry
Eligibility
72 Months to 203 Months
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Madera, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 30, 2026, 6:13 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

NCT00832650
View directory record Official record
Conditions
Healthy
Interventions
fesoterodine fumarate, placebo, solifenacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 24, 2010 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function

NCT00596518
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
PF-00734200
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 77 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

NCT00800618
View directory record Official record
Conditions
Endometriosis
Interventions
PF-02413873 100 mg QD, PF-02413873 1500 mg QD, PF-02413873 20 mg QD, PF-02413873 500 mg QD, PF-02413873 Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
New Haven, Connecticut • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Oct 30, 2026, 6:13 AM EDT
Recruiting Phase 2 Interventional

A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

NCT07470879
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
10
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 6:13 AM EDT
Completed No phase listed Observational Results available

Treatment Patterns Among Patients With Venous Thromboembolism in the United States

NCT05795062
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
apixaban, warfarin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
13,945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Not applicable Interventional Results available

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

NCT00428220
View directory record Official record
Conditions
Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer, Non-Small Cell Lung Cancer, Thyroid Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer, Advanced Gastric Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma, Pancreatic Islet Cell Carcinoma, Pancreatic Neuroendocrine Tumor
Interventions
sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Atlanta, Georgia • Maywood, Illinois • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 3 Interventional

Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

NCT00137462
View directory record Official record
Conditions
Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
48
States / cities
Huntsville, Alabama • Union Grove, Alabama • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2007 · Synced Oct 30, 2026, 6:13 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

NCT07729462
View directory record Official record
Conditions
Preventive Treatment of Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
19
States / cities
Scottsdale, Arizona • Canoga Park, California • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease

NCT02114203
View directory record Official record
Conditions
Phase 1 Sickle Cell
Interventions
PDE9i, placebo for PDE9i
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Chicago, Illinois • Boston, Massachusetts • Brooklyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

NCT04616027
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Impairment, Healthy
Interventions
PF-06882961 20 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 30, 2026, 6:13 AM EDT
Recruiting Phase 2 Interventional

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

NCT06974786
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions
Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 4 Interventional

Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection

NCT00419991
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
Tigecycline
Drug
Lead sponsor
CPL Associates
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Huntsville, Alabama • Marietta, Georgia • Cumberland, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 30, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

NCT00375674
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
Sunitinib malate, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
12
States / cities
Los Angeles, California • Atlanta, Georgia • Marrero, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 30, 2026, 6:13 AM EDT